Summary | |
---|---|
Symbol | DCAKD |
Name | dephospho-CoA kinase domain containing |
Aliases | FLJ22955; Dephospho-CoA kinase domain-containing protein |
Chromosomal Location | 17q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | - |
Domain |
PF01121 Dephospho-CoA kinase |
Function |
- |
Biological Process |
GO:0006164 purine nucleotide biosynthetic process GO:0006732 coenzyme metabolic process GO:0009108 coenzyme biosynthetic process GO:0009116 nucleoside metabolic process GO:0009119 ribonucleoside metabolic process GO:0009150 purine ribonucleotide metabolic process GO:0009152 purine ribonucleotide biosynthetic process GO:0009163 nucleoside biosynthetic process GO:0009165 nucleotide biosynthetic process GO:0009260 ribonucleotide biosynthetic process GO:0015936 coenzyme A metabolic process GO:0015937 coenzyme A biosynthetic process GO:0033865 nucleoside bisphosphate metabolic process GO:0033866 nucleoside bisphosphate biosynthetic process GO:0033875 ribonucleoside bisphosphate metabolic process GO:0034030 ribonucleoside bisphosphate biosynthetic process GO:0034032 purine nucleoside bisphosphate metabolic process GO:0034033 purine nucleoside bisphosphate biosynthetic process GO:0042278 purine nucleoside metabolic process GO:0042451 purine nucleoside biosynthetic process GO:0042455 ribonucleoside biosynthetic process GO:0046128 purine ribonucleoside metabolic process GO:0046129 purine ribonucleoside biosynthetic process GO:0046390 ribose phosphate biosynthetic process GO:0051186 cofactor metabolic process GO:0051188 cofactor biosynthetic process GO:0072522 purine-containing compound biosynthetic process GO:1901293 nucleoside phosphate biosynthetic process GO:1901657 glycosyl compound metabolic process GO:1901659 glycosyl compound biosynthetic process |
Molecular Function |
GO:0004140 dephospho-CoA kinase activity |
Cellular Component | - |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | DCAKD |
Name | dephospho-CoA kinase domain containing |
Aliases | FLJ22955; Dephospho-CoA kinase domain-containing protein |
Chromosomal Location | 17q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between DCAKD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | DCAKD |
Name | dephospho-CoA kinase domain containing |
Aliases | FLJ22955; Dephospho-CoA kinase domain-containing protein |
Chromosomal Location | 17q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of DCAKD in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | DCAKD |
Name | dephospho-CoA kinase domain containing |
Aliases | FLJ22955; Dephospho-CoA kinase domain-containing protein |
Chromosomal Location | 17q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of DCAKD in various data sets.
|
Points in the above scatter plot represent the mutation difference of DCAKD in various data sets.
|
Summary | |
---|---|
Symbol | DCAKD |
Name | dephospho-CoA kinase domain containing |
Aliases | FLJ22955; Dephospho-CoA kinase domain-containing protein |
Chromosomal Location | 17q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DCAKD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | DCAKD |
Name | dephospho-CoA kinase domain containing |
Aliases | FLJ22955; Dephospho-CoA kinase domain-containing protein |
Chromosomal Location | 17q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DCAKD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DCAKD. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | DCAKD |
Name | dephospho-CoA kinase domain containing |
Aliases | FLJ22955; Dephospho-CoA kinase domain-containing protein |
Chromosomal Location | 17q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DCAKD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | DCAKD |
Name | dephospho-CoA kinase domain containing |
Aliases | FLJ22955; Dephospho-CoA kinase domain-containing protein |
Chromosomal Location | 17q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of DCAKD expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | DCAKD |
Name | dephospho-CoA kinase domain containing |
Aliases | FLJ22955; Dephospho-CoA kinase domain-containing protein |
Chromosomal Location | 17q21.31 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between DCAKD and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |